Google Ad

DCGI nod to Serum-Oxford covid-19 vaccine for section 2, Three scientific trials in India – Home Health Choices

By Priyanka Sharma

New Delhi: India’s high drug regulator– Drugs Controller General of India (DCGI) has granted permission to Serum Institute of India (SII) to conduct section 2 and three human scientific trials in India on the potential covid-19 vaccine, a senior authorities official mentioned.

“After a thorough evaluation, the DCGI has given approval to SII to perform phase-II, III clinical trial based on the recommendations of the Subject Expert Committee (SEC),” the official supply informed ANI.

“As a rapid regulatory response, the proposal was deliberated in the SEC through a virtual meeting earlier this week. And after considering the data generated on the vaccine in phase-1, 2 of the Oxford University trial, the committee recommended granting permission to conduct phase 2, 3 clinical trials of COVISHIELD (SII-ChAdOx1 nCoV-19) healthy adult subjects at risk in the country,” the official mentioned.

As per the research design, every topic will probably be administered two doses four weeks aside (First dose on Day 1 and Second dose on Day 29) following which the protection and immunogenicity will probably be assessed at predefined intervals, the official mentioned.

According to the official, the pharma agency has to submit security knowledge, evaluated by the Data Safety Monitoring Board (DSMB), to the Central Drugs Standard Control Organization (CDSCO) earlier than it might probably proceed to phase-Three of the scientific trial.

Last week ANI had reported that the home pharma big had made an software to DCGI for grant of permission to conduct section 2, Three scientific trials of coronavirus vaccine (ChAdOxlnCoV- 19) in India.

The vaccine was manufactured by Serum in India below technical collaboration with Oxford University/Astra Zeneca and is known as as COVISHIELD (SII-ChAdOx1 nCoV-19).

Currently, section 2, Three scientific trials of the Oxford sponsor vaccine is ongoing in United Kingdom, section Three scientific trial in Brazil and section 1, 2 scientific trials in South Africa.

It is pertinent to notice that COVISHIELD (SII-ChAdOx1 nCoV-19) vaccine comprises the replication-deficient simian adenovirus vector ChAdOx1, containing the structural floor glycoprotein (Spike protein) antigens of SARS-CoV-2.

Latest Updates

Related Post